Dare Bioscience, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sabrina Martucci Johnson
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3655 Nobel Drive San Diego CA United States of America 92122
- IPO Date
- Apr 10, 2014
- CIK
- 0001401914
- Website
- darebioscience.com
- Similar Companies
- Business
- Daré Bioscience, Inc. (Nasdaq: DARE) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for women's health conditions. The company advances a diversified portfolio of proprietary product candidates targeting unmet needs in women's reproductive health, sexual health, and vaginal health; key programs include Ovaprene, a hormone-free, on-demand, monthly-use intravaginal ring for contraception currently in Phase 3 clinical development, Seysara for treatment of acne vulgaris in adult women, and bivosiran for potential use in endometriosis-associated pain, among others. Daré operates primarily in the United States with clinical trials and partnerships extending to global markets, and maintains its headquarters in San Diego, California, where it was founded in 2007 following the spin-off from Biosite Inc. The company's core offerings encompass preclinical and clinical-stage therapeutics delivered via novel drug delivery platforms such as silicone rings, gels, films, and mini-tablets designed for non-systemic or localized administration to minimize side effects. Daré provides research and development services through strategic collaborations with leading contract manufacturers and research organizations, serving healthcare providers, patients, and pharmaceutical partners in the women's health sector. Subsidiaries include Daré NewCo, LLC, which holds certain intellectual property assets. In the last two years, Daré Bioscience has expanded its pipeline through key strategic advancements, including the initiation of the Phase 3 AMagine trial for Ovaprene in 2023 with enrollment completion targeted for late 2025, and positive interim data from earlier studies supporting regulatory progress. The company secured a $15 million non-dilutive funding commitment from the U.S. Biomedical Advanced Research and Development Authority (BARDA) in 2024 to support women's health initiatives, alongside partnerships with Quotient Sciences for manufacturing scale-up and laboratoirés Genevir for gene silencing technologies in gynecology. These developments reflect Daré's shift toward late-stage commercialization readiness, with plans for potential U.S. FDA submissions by 2026 and international expansion into Europe and Asia.
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
On National Viagra Day, Women Finally Claim Their Turn:
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
Daré Bioscience Participates in Virtual Investor “What This Means” Segment
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer